

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7241640
<b>Application Number:</b>	10663506
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1850
<b>Title of Invention:</b>	ORAL FORMULATIONS
<b>First Named Inventor/Applicant Name:</b>	Muhammad Ashraf
<b>Customer Number:</b>	38199
<b>Filer:</b>	Robert J. Duminiak
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	AM-101106US
<b>Receipt Date:</b>	18-MAR-2010
<b>Filing Date:</b>	15-SEP-2003
<b>Time Stamp:</b>	19:48:37
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$950
RAM confirmation Number	7442
Deposit Account	083040
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		AM101106US_031810RCEandI DSfiling.pdf	913798  21c147d9c26cd579a6653173994aea1b1c ebc6d	yes	20
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Request for Continued Examination (RCE)		1		1
	Terminal Disclaimer Filed		2		2
	Amendment Submitted/Entered with Filing of CPA/RCE		3		3
	Claims		4		7
	Applicant Arguments/Remarks Made in an Amendment		8		9
	Transmittal Letter		10		13
	Information Disclosure Statement (IDS) Filed (SB/08)		14		16
	Foreign Reference		17		17
	Transmittal Letter		18		20
<b>Warnings:</b>					
<b>Information:</b>					
2	Foreign Reference	WO_02_40000.pdf	559066  4bfefed8c74ab50a5c7089c8f6c759faa1051d4 b2a	no	13
<b>Warnings:</b>					
<b>Information:</b>					
3	Fee Worksheet (PTO-875)	fee-info.pdf	31597  a213bae791ea111b3524090cf81bef8a142 15a2	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			1504461		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.